PGI Advantage Tome's programmable genomic integration (PGI) platform enables insertion of genetic sequences of any size at any genomic location with site specific precision. This capability positions Tome as a strategic partner for biotech and pharma companies developing gene therapies and cell therapies that require precise genome integration. Sales opportunities include licensing access to PGI, co development partnerships to integrate PGI into clinical programs, or contract collaboration for preclinical work and manufacturing scale up to support regulatory submissions, with emphasis on liver, hematopoietic and other high value targets.

Collaboration Proof Recent collaboration with Genevant Sciences demonstrates demand for PGI in gene editing therapeutics for a rare liver disorder, validating Tome as a credible partner for disease focused programs. This track record suggests expansion opportunities with other gene editing and liver disease developers, as well as potential licensing or subcontracting arrangements to accelerate joint programs and bring therapies to patients faster.

Funding Momentum Strong funding momentum with a 213 million series A and B round led by Andreessen Horowitz and other top investors signals validation and the ability to support ambitious partnerships, co development, and manufacturing scale up. For business development, this creates openings to engage portfolio companies of these investors or to pursue strategic conversations with large biotech firms seeking to accelerate program timelines through PGI enabled processes.

Leadership Momentum New board member Daniel Curran brings deep clinical development and industry experience, underscoring Tome readiness to scale strategic collaborations, manage regulatory pathways, and structure joint development deals. This leadership angle can be a compelling talking point when engaging pharma and CRO partners about program governance and risk sharing.

Regional Access Based in Watertown, Massachusetts near Boston, Tome sits in a dense biotech ecosystem with abundant CROs contract manufacturers and potential customers. This proximity reduces partnership friction and supports co development licensing and manufacturing scale up conversations with local players and adjacent regions.